Indication
penile cancer
2 clinical trials
4 products
Clinical trial
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Status: Recruiting, Estimated PCD: 2025-02-28
Product
CabozantinibProduct
IpilimumabProduct
NivolumabClinical trial
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Pembrolizumab